TrialFind
Saved trials

Filters

Status

Phase

Age group

TrialFind

Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

PrivacyData sourcesRegulatory infoContact
CompletedPhase 4

Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes

Glucose-induced insulin secretion is often diminished in hyperglycaemic patients with type 2 diabetes. The investigators examined, whether chronic basal insulin treatment with insulin glargine lead to improvements in glucose-induced insulin

Bochum, GermanyView details
TerminatedEARLY_Phase 1

Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

The purpose of this study is to determine with the administration of amiloride, observe an enhanced natriuresis, reduction in blood pressure and weight compared to the administration of hydrochlorothiazide in Type 2 Diabetics.

Albuquerque, New Mexico, United StatesView details
CompletedPhase 3

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.

Phoenix, Arizona, United States+181 moreView details
Completed

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects

A multi-year clinical study to improve tools for measuring the function of insulin-producing beta cells in people with type 2 diabetes mellitus.

San Antonio, Texas, United StatesView details
UnknownN/A

Evaluation of the Metformin Effect on Methylglyoxal in Patients With Type 2 Diabetes

This study is designed to investigate the effects of metformin, a commonly prescribed first line medication for diabetes and recommended for prediabetes, on the levels of the potentially tissue damaging reactive product (MG) in the blood an

Multiple locationsView details
Active, not recruitingPhase 1

Genetics of Response to Canagliflozin

Five daily doses of canagliflozin (300 mg) will be administered to healthy volunteers. Pharmacodynamic responses to canagliflozin will be assessed both at 2 days and 6 days after administration of the first dose of canagliflozin.

Multiple locationsView details
Not yet recruiting

20 Years Results by HBP and DBP in Patients With Type 2 Diabetes Mellitus After Following-up

Participants were examined using the methods reported previous. All chemical laboratory data were obtained at each clinic visit in the morning in a non-fasting state.

Multiple locationsView details
RecruitingPhase 2

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA.

Rochester, Minnesota, United StatesView details
CompletedPhase 3

The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

The goal of this study is to learn whether semaglutide (treatment for type 2 diabetes and obesity) can improve signs and symptoms of hypogonadism in men with type 2 diabetes, obesity and hypogonadism (a condition when levels of testosterone

Ljubljana, SloveniaView details
TerminatedPhase 2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects

The principal objective of this study is to evaluate the safety and tolerability of repeated doses of EV-077-3201-2TBS given to diabetic subjects over a 4 week treatment period. The secondary aim of this initial Phase IIa study is to evalua

Neuss, GermanyView details
UnknownN/A

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

Shanghai, Shanghai Municipality, ChinaView details
CompletedN/A

Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord)

The purpose of this study is to identify in prediabetic subjects, physiopathological changes involved in the evolution to type 2 diabetes mellitus and to identify new biomarkers of type 2 diabetes risk in this population.

Lille, FranceView details
CompletedPhase 3

Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin

This trial is conducted in Europe. The aim of this trial is to compare two insulin delivery pens in the everyday life setting of patients with diabetes treated with insulin.

Vienna, Austria+22 moreView details
Completed

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus another gluc

Wilmington, Delaware, United States+16 moreView details
CompletedN/A

Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy

Currently in the United States, the achieved level of glycemic control for adult Latinos with type 2 diabetes (T2D) is sub-optimal compared to the non-Latino Caucasian population. Among Latinos with T2D, there are unique barriers, such as s

Santa Barbara, California, United StatesView details
CompletedPhase 3

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

A 16 week open-label study with subjects receiving background metformin monotherapy. 150 subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open label rosiglitazone, or open-label sitagliptin.

La Mesa, California, United States+19 moreView details
CompletedPhase 1 / Phase 2

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

This study is being conducted to assess the overall safety and tolerability of a single intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects with Type 2 Diabetes inadequately controlled on Metformin.

Garden Grove, California, United States+17 moreView details
RecruitingN/A

Health Without Barriers/Salud Sin Barreras- Northern Colorado

The overarching goal of this work is to address the limited access to evidence-based health behavior and lifestyle interventions for youth and families most impacted by preventable chronic diseases, including obesity and type 2 diabetes. In

Fort Collins, Colorado, United StatesView details
RecruitingN/A

A Fruit and Vegetable Prescription Program

Dietary intake of fruits and vegetables (F\&V) is a cornerstone for the treatment of type 2 diabetes, however less than 16% of Hispanic adults consume the recommended number of servings each day. F\&V prescription (F\&V Rx) programs are emb

Reading, Pennsylvania, United StatesView details
CompletedPhase 3

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.

Chūbu, Japan+4 moreView details
Load more trials